| APSAC | 1) Acylating the Plasminogen Streptokinase Activated Complex 2) Anisoylat... |
|---|---|
| APSAC | acylated plasminogen-streptokinase activator complex; anisoylated plasminogen streptokinase activato... |
| rt-PA | recombinant tissue-Plasminogen Activator = Alteplase |
| tPA | tissue Plasminogen Activator |
| EPA | eicosapentaenoic acid; empiric phrase association; Environmental Protection Agency; erect posterior-... |
| APSAC | Anisoylated Plasminogen Streptokinase Activator Complex |
|---|---|
| Glu-Plg | Glu-plasminogen |
| PG | Plasminogen |
| PGN | Plasminogen |
| PLG | Plasminogen |
| plasminogen inactivators | <chemical> Important modulators of the activity of plasminogen activator. Four inhibitors, all belonging to the serpin family of proteins, have been implicated in plasminogen activation inhibition. They are pai-1, pai-2, protease-nexin, and protein c inhibitor (pai-3). All inhibit both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
|---|
| complement 1 inactivators | Compounds which inhibit, antagonise, or inactivate complement 1. A well-known inhibitor is a serum glycoprotein believed to be alpha-2-neuroaminoglycoprotein. It inhibits the activated (esterase) form of complement 1 as well as kinin-forming, coagulation, and fibrinolytic systems. Deficiency of this inactivator has been found in patients with hereditary angioneurotic oedema. These compounds are members of the serpin superfamily. (12 Dec 1998) |
|---|---|
| complement 3b inactivators | Compounds which inhibit, antagonise, or inactivate complement 3b. A well-known inhibitor is a beta-globulin which cleaves c3b into inactive fragments c3c and c3d. C3bina plays a key role in the regulation of the complement system by blocking the cytolytic sequence and preventing recruitment of the properdin amplification loop. (12 Dec 1998) |
| complement inactivators | Serum proteins which act at key sites in the complement sequence to modulate or prevent the progression of the reaction. Absence of these factors leads to uncontrolled activation of the complement system with accompanying disease. (12 Dec 1998) |
| plasminogen | <enzyme> The inactive precursor of plasmin. (18 Nov 1997) |
| plasminogen activator | <enzyme> Serine protease that acts on plasminogen to generate plasmin. Has also been implicated in invasiveness and is produced by many normal and invasive cells. The vascular form (tPA, 55 kD) is very similar to tissue plasminogen activator (uPA, 70 kD) and to streptokinase and urokinase. (18 Nov 1997) |
| plasminogen activator inhibitor 1 | <chemical> A member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| plasminogen activator inhibitor 2 | <chemical> Member of the serpin family of proteins. It inhibits both the tissue-type and urokinase-type plasminogen activator. Pharmacological action: serine proteinase inhibitors. (12 Dec 1998) |
| tissue plasminogen activator | <enzyme> Plasma serine protease, one of a closely related group of plasminogen activators. Contains an EGF like domain and multiple copies of the kringle domain. (18 Nov 1997) |
| kidney plasminogen activator | <protein> A precursor to the enzyme urokinase that has blood clotting properties. (14 Nov 1997) |
Synonyms : BAE-PAI, Endothelial Plasminogen Activator Inhibitors, Placental Plasminogen Activator Inhibitors, Plasminogen Activator Inhibitors, Endothelial, Plasminogen Activator Inhibitors, Placental, Inactivators, Plasminogen, Inhibitors, Plasminogen Activator
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|